TY - JOUR T1 - Knock-In Rat Lines with Cre Recombinase at the Dopamine D1 and Adenosine 2a Receptor Loci JF - eneuro JO - eNeuro DO - 10.1523/ENEURO.0163-19.2019 VL - 6 IS - 5 SP - ENEURO.0163-19.2019 AU - Jeffrey R. Pettibone AU - Jai Y. Yu AU - Rifka C. Derman AU - Thomas W. Faust AU - Elizabeth D. Hughes AU - Wanda E. Filipiak AU - Thomas L. Saunders AU - Carrie R. Ferrario AU - Joshua D. Berke Y1 - 2019/09/01 UR - http://www.eneuro.org/content/6/5/ENEURO.0163-19.2019.abstract N2 - Genetically modified mice have become standard tools in neuroscience research. Our understanding of the basal ganglia in particular has been greatly assisted by BAC mutants with selective transgene expression in striatal neurons forming the direct or indirect pathways. However, for more sophisticated behavioral tasks and larger intracranial implants, rat models are preferred. Furthermore, BAC lines can show variable expression patterns depending upon genomic insertion site. We therefore used CRISPR/Cas9 to generate two novel knock-in rat lines specifically encoding Cre recombinase immediately after the dopamine D1 receptor (Drd1a) or adenosine 2a receptor (Adora2a) loci. Here, we validate these lines using in situ hybridization and viral vector mediated transfection to demonstrate selective, functional Cre expression in the striatal direct and indirect pathways, respectively. We used whole-genome sequencing to confirm the lack of off-target effects and established that both rat lines have normal locomotor activity and learning in simple instrumental and Pavlovian tasks. We expect these new D1-Cre and A2a-Cre rat lines will be widely used to study both normal brain functions and neurological and psychiatric pathophysiology. ER -